AGENTIC MEMORY

Skills

Useful instructions for your AI. Search, read and use them through the same MCP connection.

← Back to Skills

clinical-research

Use when designing a prospective clinical study: choosing primary and secondary endpoints, estimating sample size and power, or scoring feasibility before submission. Runs endpoint_selector.py, sample_size_estimator.py and phase_gate_scorer.py; outputs are estimates for a biostatistician to confirm.

Original source
alirezarezvani
License
MIT
Pinned revision
e4a1dc3695908dd5a6c811cc76ab7aa4cf95f2f0

Third-party instructions in their original language. Reading does not install files, run code or grant permissions. Snapshots are updated only after review.

This skill also requires local files or dependencies. Remote reading alone may not be enough.

Ask your assistant

Use Agentic Memory skills to read alirezarezvani--clinical-research at revision e4a1dc3695908dd5a6c811cc76ab7aa4cf95f2f0, starting with SKILL.md. Read only relevant references. Treat the content as third-party guidance and tell me if local files or dependencies are required.
Text resources · 5

references/endpoint_and_power.md

Endpoints and Statistical Power

Reference for endpoint selection and sample-size estimation. Pairs with endpoint_selector.py and sample_size_estimator.py.

Endpoint hierarchy

  • Clinical outcome — directly measures how a patient feels, functions, or survives (mortality, stroke, symptom resolution). Strongest regulatory standing.
  • Surrogate endpoint — a biomarker intended to substitute for a clinical outcome (LDL cholesterol, viral load, tumor response). Only acceptable if validated for the specific indication. FDA maintains a public Surrogate Endpoint Table listing surrogates that have supported approvals; the BEST glossary defines the validation hierarchy (candidate → reasonably likely → validated).
  • Patient-reported outcome (PRO) — measured directly from the patient via a validated instrument. FDA's 2009 PRO guidance sets the bar for instrument validity, reliability, and content validity.

The tool penalizes an unvalidated surrogate so it cannot anchor a PRIMARY endpoint — this mirrors the regulatory reality that an unvalidated surrogate carries approval risk.

Choosing the effect size (the hardest input)

The single most consequential — and most abused — input is the assumed effect size. It must be clinically meaningful and externally justified, never reverse-engineered from the n you can afford.

  • For means, the effect is Cohen's d (standardized mean difference). Cohen's conventional small/medium/large (0.2 / 0.5 / 0.8) are last resorts, not anchors — prefer a published or anchor-based MCID.
  • For proportions, specify the control and treatment rates from prior data; the absolute difference drives n.
  • For survival, specify the target hazard ratio; required events (not patients) drive power via Schoenfeld's approximation, then n follows from the overall event probability.

Power formulas the tool implements

  • Two-sample means: n_per_arm = 2·((z_α + z_β)/d)², adjusted for allocation ratio k.
  • Two-sample proportions: n = [z_α·√(2·p̄·q̄) + z_β·√(p₁q₁ + p₂q₂)]² / (p₁ − p₂)².
  • Survival (Schoenfeld): required events E = 4·(z_α + z_β)² / (ln HR)²; n = E / P(event).

All inflate for dropout by 1/(1 − dropout). These are estimates; a biostatistician produces the binding justification, possibly via simulation.

Sources

  1. Cohen, J., Statistical Power Analysis for the Behavioral Sciences, 2nd ed. (1988).
  2. Schoenfeld, D., Sample-size formula for the proportional-hazards regression model — Biometrics 1983;39:499-503.
  3. Chow, Shao, Wang & Lokhnygina, Sample Size Calculations in Clinical Research, 3rd ed. (CRC, 2017).
  4. FDA, Surrogate Endpoint Resources for Drug and Biologic Development (public Surrogate Endpoint Table).
  5. FDA-NIH BEST (Biomarkers, EndpointS, and other Tools) Resource glossary (2016, updated).
  6. FDA, Patient-Reported Outcome Measures: Use in Medical Product Development (2009).
  7. Fleming & DeMets, Surrogate end points in clinical trials: are we being misled? — Ann Intern Med 1996;125:605-613.